Sometimes referred to as “irrational drug design,” this refers to the drug design technique of generating large numbers of diverse candidate molecules (e.g., pieces of DNA, RNA, proteins, or other organic moieties) at random (via a variety of methods). These diverse candidate molecules are then tested to see which is best at working against a disease/condition (e.g., fitting a cell receptor, or category of receptors relevant to the disease in question). Molecular candidates that show promise (e.g., via a “pretty good fit” to receptor) are then produced in larger quantities (e.g., via Polymerase Chain Reaction techniques) along with additional molecules that are similar though slightly different in structure (e.g., via site-directed mutagenesis) in an attempt to create a molecule that is a “perfect fit” (e.g., to receptor).